Linking environmental carcinogen exposure to TP53 mutations in human tumours using the human TP53 knock-in (Hupki) mouse model

FEBS Journal

Volumn 277, Issue 12, 2010, Pages 2567-2583

  Kucab, Jill E ^a   Phillips, David H ^a   Arlt, Volker M ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Cancer aetiology; Environmental carcinogen; Hupki; Immortalization; Mutation assay; TP53

Indexed keywords

3 NITROBENZANTHRONE; ARISTOLOCHIC ACID; BENZO[A]PYRENE; PROTEIN P53; TOBACCO SMOKE;

CANCER SUSCEPTIBILITY; CARCINOGEN DNA INTERACTION; CARCINOGENESIS; CELL IMMORTALIZATION; CHEMICAL CARCINOGENESIS; ENVIRONMENTAL EXPOSURE; EXCISION REPAIR; EXHAUST GAS; FIBROBLAST CULTURE; GENE MUTATION; GENE TARGETING; GENETIC POLYMORPHISM; GENOTOXICITY; HUMAN; INTERSTITIAL NEPHRITIS; LUNG CANCER; MISSENSE MUTATION; MUTAGENESIS; NONHUMAN; NUCLEIC ACID BASE SUBSTITUTION; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; SKIN CANCER; ULTRAVIOLET IRRADIATION; UROGENITAL TRACT CANCER; XENOBIOTIC METABOLISM;

EID: 77953219808     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2010.07676.x     Document Type: Review

References (121)

1. Wild CP (2009) Environmental exposure measurement in cancer epidemiology. Mutagenesis 24, 117 125.
2. Phillips DH (1999) Polycyclic aromatic hydrocarbons in the diet. Mutat Res 443, 139 147.
3. Phillips DH Arlt VM (2009) Genotoxicity: damage to DNA and its consequences. EXS 99, 87 110.
4. Hanahan D Weinberg RA (2000) The hallmarks of cancer. Cell 100, 57 70.
5. Hainaut P Hollstein M (2000) p53 and human cancer: the first ten thousand mutations. Adv Cancer Res 77, 81 137.
6. Malkin D, Li FP, Strong LC, Fraumeni JF Jr., Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA et al. (1990) Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250, 1233 1238.
7. Besaratinia A Pfeifer GP (2006) Investigating human cancer etiology by DNA lesion footprinting and mutagenicity analysis. Carcinogenesis 27, 1526 1537.
8. Yee KS Vousden KH (2005) Complicating the complexity of p53. Carcinogenesis, 26, 1317 1322.
9. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT Weinberg RA (1994) Tumor spectrum analysis in p53-mutant mice. Curr Biol, 4, 1 7.
10. Michael D Oren M (2003) The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol 13, 49 58.
11. Hammond EM Giaccia AJ (2005) The role of p53 in hypoxia-induced apoptosis. Biochem Biophys Res Commun 331, 718 725.
12. Meek DW (2009) Tumour suppression by p53: a role for the DNA damage response? Nat Rev Cancer 9, 714 723.
13. Kruse JP Gu W (2009) Modes of p53 regulation. Cell 137, 609 622.
14. Laptenko O Prives C (2006) Transcriptional regulation by p53: one protein, many possibilities. Cell Death Differ 13, 951 961.
15. Riley T, Sontag E, Chen P Levine A (2008) Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 9, 402 412.
16. Giono LE Manfredi JJ (2006) The p53 tumor suppressor participates in multiple cell cycle checkpoints. J Cell Physiol 209, 13 20.
17. Yu J Zhang L (2005) The transcriptional targets of p53 in apoptosis control. Biochem Biophys Res Commun 331, 851 858.
18. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P Olivier M (2007) Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 28, 622 629.
19. Hollstein M, Sidransky D, Vogelstein B Harris CC (1991) p53 mutations in human cancers. Science 253, 49 53.
20. Brash DE, Rudolph JA, Simon JA, Lin A, McKenna GJ, Baden HP, Halperin AJ Ponten J (1991) A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci U S A 88, 10124 10128.
21. Ziegler A, Leffell DJ, Kunala S, Sharma HW, Gailani M, Simon JA, Halperin AJ, Baden HP, Shapiro PE, Bale AE et al. (1993) Mutation hotspots due to sunlight in the p53 gene of nonmelanoma skin cancers. Proc Natl Acad Sci U S A 90, 4216 4220.
22. Pfeifer GP, Denissenko MF, Olivier M, Tretyakova N, Hecht SS Hainaut P (2002) Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene 21, 7435 7451.
23. Pfeifer GP Hainaut P (2003) On the origin of G→T transversions in lung cancer. Mutat Res 526, 39 43.
24. Staib F, Hussain SP, Hofseth LJ, Wang XW Harris CC (2003) TP53 and liver carcinogenesis. Hum Mutat 21, 201 216.
25. Montesano R, Hainaut P Wild CP (1997) Hepatocellular carcinoma: from gene to public health. J Natl Cancer Inst 89, 1844 1851.
26. Arlt VM, Stiborova M, vom Brocke J, Simoes ML, Lord GM, Nortier JL, Hollstein M, Phillips DH Schmeiser HH (2007) Aristolochic acid mutagenesis: molecular clues to the aetiology of Balkan endemic nephropathy-associated urothelial cancer. Carcinogenesis 28, 2253 2261.
27. Grollman AP, Shibutani S, Moriya M, Miller F, Wu L, Moll U, Suzuki N, Fernandes A, Rosenquist T, Medverec Z et al. (2007) Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc Natl Acad Sci U S A 104, 12129 12134.
28. Tornaletti S Pfeifer GP (1995) Complete and tissue-independent methylation of CpG sites in the p53 gene: implications for mutations in human cancers. Oncogene 10, 1493 1499.
29. Pfeifer GP (2000) p53 mutational spectra and the role of methylated CpG sequences. Mutat Res 450, 155 166.
30. Gonzalgo ML Jones PA (1997) Mutagenic and epigenetic effects of DNA methylation. Mutat Res 386, 107 118.
31. Denissenko MF, Chen JX, Tang MS Pfeifer GP (1997) Cytosine methylation determines hot spots of DNA damage in the human P53 gene. Proc Natl Acad Sci U S A 94, 3893 3898.
32. Weisenberger DJ Romano LJ (1999) Cytosine methylation in a CpG sequence leads to enhanced reactivity with benzo[a]pyrene diol epoxide that correlates with a conformational change. J Biol Chem 274, 23948 23955.
33. Tommasi S, Denissenko MF Pfeifer GP (1997) Sunlight induces pyrimidine dimers preferentially at 5-methylcytosine bases. Cancer Res 57, 4727 4730.
34. Kato S, Han SY, Liu W, Otsuka K, Shibata H, Kanamaru R Ishioka C (2003) Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci U S A 100, 8424 8429.
35. Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P Olivier M (2007) TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 26, 2157 2165.
36. Rodin SN Rodin AS (2005) Origins and selection of p53 mutations in lung carcinogenesis. Semin Cancer Biol 15, 103 112.
37. Cho Y, Gorina S, Jeffrey PD Pavletich NP (1994) Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265, 346 355.
38. Luo JL, Yang Q, Tong WM, Hergenhahn M, Wang ZQ Hollstein M (2001) Knock-in mice with a chimeric human/murine p53 gene develop normally and show wild-type p53 responses to DNA damaging agents: a new biomedical research tool. Oncogene 20, 320 328.
39. Dudgeon C, Kek C, Demidov ON, Saito S, Fernandes K, Diot A, Bourdon JC, Lane DP, Appella E, Fornace AJ Jr. et al. (2006) Tumor susceptibility and apoptosis defect in a mouse strain expressing a human p53 transgene. Cancer Res 66, 2928 2936.
40. Jaworski M, Hailfinger S, Buchmann A, Hergenhahn M, Hollstein M, Ittrich C Schwarz M (2005) Human p53 knock-in (hupki) mice do not differ in liver tumor response from their counterparts with murine p53. Carcinogenesis 26, 1829 1834.
41. Dumaz N, van Kranen HJ, de Vries A, Berg RJ, Wester PW, van Kreijl CF, Sarasin A, Daya-Grosjean L de Gruijl FR (1997) The role of UV-B light in skin carcinogenesis through the analysis of p53 mutations in squamous cell carcinomas of hairless mice. Carcinogenesis 18, 897 904.
42. Liu Z, Belharazem D, Muehlbauer KR, Nedelko T, Knyazev Y Hollstein M (2007) Mutagenesis of human p53 tumor suppressor gene sequences in embryonic fibroblasts of genetically-engineered mice. Genet Eng (N Y) 28, 45 54.
43. Arlt VM, Gingerich J, Schmeiser HH, Phillips DH, Douglas GR White PA (2008) Genotoxicity of 3-nitrobenzanthrone and 3-aminobenzanthrone in MutaMouse and lung epithelial cells derived from MutaMouse. Mutagenesis 23, 483 490.
44. Chen RH, Maher VM, Brouwer J, van de Putte P McCormick JJ (1992) Preferential repair and strand-specific repair of benzo[a]pyrene diol epoxide adducts in the HPRT gene of diploid human fibroblasts. Proc Natl Acad Sci U S A 89, 5413 5417.
45. vom Brocke J, Schmeiser HH, Reinbold M Hollstein M (2006) MEF immortalization to investigate the ins and outs of mutagenesis. Carcinogenesis 27, 2141 2147.
46. Parrinello S, Samper E, Krtolica A, Goldstein J, Melov S Campisi J (2003) Oxygen sensitivity severely limits the replicative lifespan of murine fibroblasts. Nat Cell Biol 5, 741 747.
47. Harvey DM Levine AJ (1991) p53 alteration is a common event in the spontaneous immortalization of primary BALB/c murine embryo fibroblasts. Genes Dev 5, 2375 2385.
48. Kamijo T, Zindy F, Roussel MF, Quelle DE, Downing JR, Ashmun RA, Grosveld G Sherr CJ (1997) Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 91, 649 659.
49. Hornsby PJ (2003) Mouse and human cells versus oxygen. Sci Aging Knowledge Environ 2003, PE21.
50. Rangarajan A Weinberg RA (2003) Opinion: comparative biology of mouse versus human cells: modelling human cancer in mice. Nat Rev Cancer 3, 952 959.
51. Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, Harley CB, Shay JW, Lichtsteiner S Wright WE (1998) Extension of life-span by introduction of telomerase into normal human cells. Science 279, 349 352.
52. Boehm JS Hahn WC (2005) Understanding transformation: progress and gaps. Curr Opin Genet Dev 15, 13 17.
53. Whibley C, Odell A, Nedelko T, Balaburski G, Murphy M, Liu Z, Stevens L, Walker JH, Routledge M Hollstein M (2010) Wild-type and HUPKI (human p53 knock-in) murine embryonic fibroblasts: P53/ARF pathways disruption in spontaneous escape from senescence. J Biol Chem 285, 11326 11335.
54. Liu Z, Hergenhahn M, Schmeiser HH, Wogan GN, Hong A Hollstein M (2004) Human tumor p53 mutations are selected for in mouse embryonic fibroblasts harboring a humanized p53 gene. Proc Natl Acad Sci U S A 101, 2963 2968.
55. Liu Z, Muehlbauer KR, Schmeiser HH, Hergenhahn M, Belharazem D Hollstein MC (2005) p53 mutations in benzo(a)pyrene-exposed human p53 knock-in murine fibroblasts correlate with p53 mutations in human lung tumors. Cancer Res 65, 2583 2587.
56. Feldmeyer N, Schmeiser HH, Muehlbauer KR, Belharazem D, Knyazev Y, Nedelko T Hollstein M (2006) Further studies with a cell immortalization assay to investigate the mutation signature of aristolochic acid in human p53 sequences. Mutat Res 608, 163 168.
57. Reinbold M, Luo JL, Nedelko T, Jerchow B, Murphy ME, Whibley C, Wei Q Hollstein M (2008) Common tumour p53 mutations in immortalized cells from Hupki mice heterozygous at codon 72. Oncogene 27, 2788 2794.
58. Nedelko T, Arlt VM, Phillips DH Hollstein M (2009) TP53 mutation signature supports involvement of aristolochic acid in the aetiology of endemic nephropathy-associated tumours. Int J Cancer 124, 987 990.
59. vom Brocke J, Krais A, Whibley C, Hollstein MC Schmeiser HH (2009) The carcinogenic air pollutant 3-nitrobenzanthrone induces GC to TA transversion mutations in human p53 sequences. Mutagenesis 24, 17 23.
60. Tornaletti S, Rozek D Pfeifer GP (1993) The distribution of UV photoproducts along the human p53 gene and its relation to mutations in skin cancer. Oncogene 8, 2051 2057.
61. Phillips DH (2002) Smoking-related DNA and protein adducts in human tissues. Carcinogenesis 23, 1979 2004.
62. Arlt VM, Stiborova M, Henderson CJ, Thiemann M, Frei E, Aimova D, Singh R, Gamboa da Costa G, Schmitz OJ, Farmer PB et al. (2008) Metabolic activation of benzo[a]pyrene in vitro by hepatic cytochrome P450 contrasts with detoxification in vivo: experiments with hepatic cytochrome P450 reductase null mice. Carcinogenesis 29, 656 665.
63. Denissenko MF, Pao A, Tang M Pfeifer GP (1996) Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. Science 274, 430 432.
64. Smith LE, Denissenko MF, Bennett WP, Li H, Amin S, Tang M Pfeifer GP (2000) Targeting of lung cancer mutational hotspots by polycyclic aromatic hydrocarbons. J Natl Cancer Inst 92, 803 811.
65. Denissenko MF, Pao A, Pfeifer GP Tang M (1998) Slow repair of bulky DNA adducts along the nontranscribed strand of the human p53 gene may explain the strand bias of transversion mutations in cancers. Oncogene 16, 1241 1247.
66. Vineis P Husgafvel-Pursiainen K (2005) Air pollution and cancer: biomarker studies in human populations. Carcinogenesis 26, 1846 1855.
67. IPCS (2003) Selected nitro- and nitro-oxy-polycyclic aromatic hydrocarbons. Environ Health Crit Monogr 229.
68. Tokiwa H, Sera N, Horikawa K, Nakanishi Y Shigematu N (1993) The presence of mutagens/carcinogens in the excised lung and analysis of lung cancer induction. Carcinogenesis 14, 1933 1938.
69. Enya T, Suzuki H, Watanabe T, Hirayama T Hisamatsu Y (1997) 3-Nitrobenzanthrone, a powerful bacterial mutagen and suspected human carcinogen found in diesel exhausts and airborne particulates. Environ Sci Technol 31, 2772 2776.
70. Nagy E, Zeisig M, Kawamura K, Hisamatsu Y, Sugeta A, Adachi S Moller L (2005) DNA adduct and tumor formations in rats after intratracheal administration of the urban air pollutant 3-nitrobenzanthrone. Carcinogenesis 26, 1821 1828.
71. Arlt VM (2005) 3-Nitrobenzanthrone, a potential human cancer hazard in diesel exhaust and urban air pollution: a review of the evidence. Mutagenesis 20, 399 410.
72. Arlt VM, Stiborova M, Henderson CJ, Osborne MR, Bieler CA, Frei E, Martinek V, Sopko B, Wolf CR, Schmeiser HH et al. (2005) Environmental pollutant and potent mutagen 3-nitrobenzanthrone forms DNA adducts after reduction by NAD(P)H:quinone oxidoreductase and conjugation by acetyltransferases and sulfotransferases in human hepatic cytosols. Cancer Res 65, 2644 2652.
73. Stiborova M, Dracinska H, Hajkova J, Kaderabkova P, Frei E, Schmeiser HH, Soucek P, Phillips DH Arlt VM (2006) The environmental pollutant and carcinogen 3-nitrobenzanthrone and its human metabolite 3-aminobenzanthrone are potent inducers of rat hepatic cytochromes P450 1A1 and -1A2 and NAD(P)H:quinone oxidoreductase. Drug Metab Dispos 34, 1398 1405.
74. Arlt VM, Glatt H, Muckel E, Pabel U, Sorg BL, Schmeiser HH Phillips DH (2002) Metabolic activation of the environmental contaminant 3-nitrobenzanthrone by human acetyltransferases and sulfotransferase. Carcinogenesis 23, 1937 1945.
75. Arlt VM, Schmeiser HH, Osborne MR, Kawanishi M, Kanno T, Yagi T, Phillips DH Takamura-Enya T (2006) Identification of three major DNA adducts formed by the carcinogenic air pollutant 3-nitrobenzanthrone in rat lung at the C8 and N2 position of guanine and at the N6 position of adenine. Int J Cancer 118, 2139 2146.
76. Bieler CA, Cornelius MG, Stiborova M, Arlt VM, Wiessler M, Phillips DH Schmeiser HH (2007) Formation and persistence of DNA adducts formed by the carcinogenic air pollutant 3-nitrobenzanthrone in target and non-target organs after intratracheal instillation in rats. Carcinogenesis 28, 1117 1121.
77. Arlt VM, Zhan L, Schmeiser HH, Honma M, Hayashi M, Phillips DH Suzuki T (2004) DNA adducts and mutagenic specificity of the ubiquitous environmental pollutant 3-nitrobenzanthrone in Muta Mouse. Environ Mol Mutagen 43, 186 195.
78. Hashimoto AH, Amanuma K, Hiyoshi K, Sugawara Y, Goto S, Yanagisawa R, Takano H, Masumura K, Nohmi T Aoki Y (2007) Mutations in the lungs of gpt delta transgenic mice following inhalation of diesel exhaust. Environ Mol Mutagen 48, 682 693.
79. Hashimoto AH, Amanuma K, Hiyoshi K, Takano H, Masumura K, Nohmi T Aoki Y (2006) In vivo mutagenesis in the lungs of gpt-delta transgenic mice treated intratracheally with 1,6-dinitropyrene. Environ Mol Mutagen 47, 277 283.
80. Schmeiser HH, Stiborova M Arlt VM (2009) Chemical and molecular basis of the carcinogenicity of Aristolochia plants. Curr Opin Drug Discov Devel 12, 141 148.
81. Debelle FD, Vanherweghem JL Nortier JL (2008) Aristolochic acid nephropathy: a worldwide problem. Kidney Int 74, 158 169.
82. Nortier JL, Martinez MC, Schmeiser HH, Arlt VM, Bieler CA, Petein M, Depierreux MF, De Pauw L, Abramowicz D, Vereerstraeten P et al. (2000) Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med 342, 1686 1692.
83. Lemy A, Wissing KM, Rorive S, Zlotta A, Roumeguere T, Muniz Martinez MC, Decaestecker C, Salmon I, Abramowicz D, Vanherweghem JL et al. (2008) Late onset of bladder urothelial carcinoma after kidney transplantation for end-stage aristolochic acid nephropathy: a case series with 15-year follow-up. Am J Kidney Dis 51, 471 477.
84. Lord GM, Cook T, Arlt VM, Schmeiser HH, Williams G Pusey CD (2001) Urothelial malignant disease and Chinese herbal nephropathy. Lancet 358, 1515 1516.
85. Schmeiser HH, Bieler CA, Wiessler M, van Ypersele de Strihou C Cosyns JP (1996) Detection of DNA adducts formed by aristolochic acid in renal tissue from patients with Chinese herbs nephropathy. Cancer Res 56, 2025 2028.
86. Arlt VM, Ferluga D, Stiborova M, Pfohl-Leszkowicz A, Vukelic M, Ceovic S, Schmeiser HH Cosyns JP (2002) Is aristolochic acid a risk factor for Balkan endemic nephropathy-associated urothelial cancer? Int J Cancer 101, 500 502.
87. Stiborova M, Frei E, Arlt VM Schmeiser HH (2008) Metabolic activation of carcinogenic aristolochic acid, a risk factor for Balkan endemic nephropathy. Mutat Res 658, 55 67.
88. Lord GM, Hollstein M, Arlt VM, Roufosse C, Pusey CD, Cook T Schmeiser HH (2004) DNA adducts and p53 mutations in a patient with aristolochic acid-associated nephropathy. Am J Kidney Dis 43, e11 e17.
89. Arlt VM, Schmeiser HH Pfeifer GP (2001) Sequence-specific detection of aristolochic acid-DNA adducts in the human p53 gene by terminal transferase-dependent PCR. Carcinogenesis 22, 133 140.
90. Grosse Y, Baan R, Straif K, Secretan B, El Ghissassi F, Bouvard V, Benbrahim-Tallaa L, Guha N, Galichet L Cogliano V (2009) A review of human carcinogens - part A: pharmaceuticals. Lancet Oncol 10, 13 14.
91. Cahilly-Snyder L, Yang-Feng T, Francke U George DL (1987) Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line. Somat Cell Mol Genet 13, 235 244.
92. Zou X, Ray D, Aziyu A, Christov K, Boiko AD, Gudkov AV Kiyokawa H (2002) Cdk4 disruption renders primary mouse cells resistant to oncogenic transformation, leading to Arf/p53-independent senescence. Genes Dev 16, 2923 2934.
93. Jacobs JJ, Keblusek P, Robanus-Maandag E, Kristel P, Lingbeek M, Nederlof PM, van Welsem T, van de Vijver MJ, Koh EY, Daley GQ et al. (2000) Senescence bypass screen identifies TBX2, which represses Cdkn2a (p19(ARF)) and is amplified in a subset of human breast cancers. Nat Genet 26, 291 299.
94. Shvarts A, Brummelkamp TR, Scheeren F, Koh E, Daley GQ, Spits H Bernard R (2010) A senescence rescue screen identifies BCL6 as an inhibitor of anto-proliferative p19Arf-p53 signaling. Genes Dev 16, 681 686.
95. Liu S, Fang X, Hall H, Yu S, Smith D, Lu Z, Fang D, Liu J, Stephens LC, Woodgett JR et al. (2008) Homozygous deletion of glycogen synthase kinase 3beta bypasses senescence allowing Ras transformation of primary murine fibroblasts. Proc Natl Acad Sci U S A 105, 5248 5253.
96. Leal JF, Fominaya J, Cascon A, Guijarro MV, Blanco-Aparicio C, Lleonart M, Castro ME, Ramon YCS, Robledo M, Beach DH et al. (2008) Cellular senescence bypass screen identifies new putative tumor suppressor genes. Oncogene 27, 1961 1970.
97. Busuttil RA, Rubio M, Dolle ME, Campisi J Vijg J (2003) Oxygen accelerates the accumulation of mutations during the senescence and immortalization of murine cells in culture. Aging Cell 2, 287 294.
98. De Bont R van Larebeke N (2004) Endogenous DNA damage in humans: a review of quantitative data. Mutagenesis 19, 169 185.
99. Nebert DW Dalton TP (2006) The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis. Nat Rev Cancer 6, 947 960.
100. White PA, Douglas GR, Gingerich J, Parfett C, Shwed P, Seligy V, Soper L, Berndt L, Bayley J, Wagner S et al. (2003) Development and characterization of a stable epithelial cell line from Muta Mouse lung. Environ Mol Mutagen 42, 166 184.
101. Cheung C, Ma X, Krausz KW, Kimura S, Feigenbaum L, Dalton TP, Nebert DW, Idle JR Gonzalez FJ (2005) Differential metabolism of 2-amino-1-methyl-6- phenylimidazo[4,5-b]pyridine (PhIP) in mice humanized for CYP1A1 and CYP1A2. Chem Res Toxicol 18, 1471 1478.
102. Cheung C Gonzalez FJ (2008) Humanized mouse lines and their application for prediction of human drug metabolism and toxicological risk assessment. J Pharmacol Exp Ther 327, 288 299.
103. de Vries A, van Oostrom CT, Hofhuis FM, Dortant PM, Berg RJ, de Gruijl FR, Wester PW, van Kreijl CF, Capel PJ, van Steeg H et al. (1995) Increased susceptibility to ultraviolet-B and carcinogens of mice lacking the DNA excision repair gene XPA. Nature 377, 169 173.
104. de Vries A, Dolle ME, Broekhof JL, Muller JJ, Kroese ED, van Kreijl CF, Capel PJ, Vijg J van Steeg H (1997) Induction of DNA adducts and mutations in spleen, liver and lung of XPA-deficient/lacZ transgenic mice after oral treatment with benzo[a]pyrene: correlation with tumour development. Carcinogenesis 18, 2327 2332.
105. Luijten M, Speksnijder EN, van Alphen N, Westerman A, Heisterkamp SH, van Benthem J, van Kreijl CF, Beems RB van Steeg H (2006) Phenacetin acts as a weak genotoxic compound preferentially in the kidney of DNA repair deficient Xpa mice. Mutat Res 596, 143 150.
106. Tang JY, Hwang BJ, Ford JM, Hanawalt PC Chu G (2000) Xeroderma pigmentosum p48 gene enchances global genomic repair and suppresses UV-induced mutagenesis. Mol Cell 5, 737 744.
107. Dumaz N, van Kranen HJ, de Vries A, Berg RJ, Wester PW, van Kreijl CF, Sarasin A, Daya-Grosjean L de Gruijl FR (1997) The role of UV-B light in skin carcinogenesis through the analysis of p53 mutations in squamous cell carcinomas of hairless mice. Carcinogenesis 18, 897 904.
108. Luo JL, Tong WM, Yoon JH, Hergenhahn M, Koomagi R, Yang Q, Galendo D, Pfeifer GP, Wang ZQ Hollstein M (2001) UV-induced DNA damage and mutations in Hupki (human p53 knock-in) mice recapitulate p53 hotspot alterations in sun-exposed human skin. Cancer Res 61, 8158 8163.
109. Tong WM, Lee MK, Galendo D, Wang ZQ Sabapathy K (2006) Aflatoxin-B exposure does not lead to p53 mutations but results in enhanced liver cancer of Hupki (human p53 knock-in) mice. Int J Cancer 119, 745 749.
110. Zielinski B, Liu Z, Hollstein M, Hergenhahn M Luo JL (2002) Mouse models for generating P53 gene mutation spectra. Toxicol Lett 134, 31 37.
111. Hollstein M, Hergenhahn M, Yang Q, Bartsch H, Wang ZQ Hainaut P (1999) New approaches to understanding p53 gene tumor mutation spectra. Mutat Res 431, 199 209.
112. Song H, Hollstein M Xu Y (2007) p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Nat Cell Biol 9, 573 580.
113. Sakamuro D, Sabbatini P, White E Prendergast GC (1997) The polyproline region of p53 is required to activate apoptosis but not growth arrest. Oncogene 15, 887 898.
114. Whibley C, Pharoah PD Hollstein M (2009) p53 polymorphisms: cancer implications. Nat Rev Cancer 9, 95 107.
115. Dumont P, Leu JI, Della Pietra AC III., George DL Murphy M (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33, 357 365.
116. Bonafe M, Salvioli S, Barbi C, Trapassi C, Tocco F, Storci G, Invidia L, Vannini I, Rossi M, Marzi E et al. (2004) The different apoptotic potential of the p53 codon 72 alleles increases with age and modulates in vivo ischaemia-induced cell death. Cell Death Differ 11, 962 973.
117. Marin MC, Jost CA, Brooks LA, Irwin MS, O'Nions J, Tidy JA, James N, McGregor JM, Harwood CA, Yulug IG et al. (2000) A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet 25, 47 54.
118. Furihata M, Takeuchi T, Matsumoto M, Kurabayashi A, Ohtsuki Y, Terao N, Kuwahara M Shuin T (2002) p53 mutation arising in Arg72 allele in the tumorigenesis and development of carcinoma of the urinary tract. Clin Cancer Res 8, 1192 1195.
119. Hu Y, McDermott MP Ahrendt SA (2005) The p53 codon 72 proline allele is associated with p53 gene mutations in non-small cell lung cancer. Clin Cancer Res 11, 2502 2509.
120. Nelson HH, Wilkojmen M, Marsit CJ Kelsey KT (2005) TP53 mutation, allelism and survival in non-small cell lung cancer. Carcinogenesis 26, 1770 1773.
121. Szymanowska A, Jassem E, Dziadziuszko R, Borg A, Limon J, Kobierska-Gulida G, Rzyman W Jassem J (2006) Increased risk of non-small cell lung cancer and frequency of somatic TP53 gene mutations in Pro72 carriers of TP53 Arg72Pro polymorphism. Lung Cancer 52, 9 14.